MRKR - Marker Therapeutics Inc Stock Price, Fair Value and News

4.50USD+0.07 (+1.58%)Delayed as of 24 Apr 2024, 02:58 pm ET

Market Summary

USD4.50+0.07

Delayedas of 24 Apr 2024, 02:58 pm

1.58%

MRKR Stock Price

View Fullscreen

MRKR RSI Chart

MRKR Valuation

Market Cap

39.4M

Price/Earnings (Trailing)

-4.79

Price/Sales (Trailing)

5.79

EV/EBITDA

-1.73

Price/Free Cashflow

-2.4

MRKR Price/Sales (Trailing)

MRKR Profitability

EBT Margin

-206.17%

Return on Equity

-58.61%

Return on Assets

-48.09%

Free Cashflow Yield

-41.68%

MRKR Fundamentals

MRKR Revenue

Revenue (TTM)

6.8M

Rev. Growth (Yr)

39.17%

Rev. Growth (Qtr)

310.13%

MRKR Earnings

Earnings (TTM)

-8.2M

Earnings Growth (Yr)

27.31%

Earnings Growth (Qtr)

Breaking Down MRKR Revenue

52 Week Range

0.769.68

(Low)(High)

Last 7 days

0.7%

Last 30 days

-9.8%

Last 90 days

6.2%

Trailing 12 Months

381.5%

How does MRKR drawdown profile look like?

MRKR Financial Health

Current Ratio

5.57

MRKR Investor Care

Shares Dilution (1Y)

1.17%

Diluted EPS (TTM)

-0.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.3M	7.3M	6.5M	6.8M
2022	1.8M	2.4M	2.9M	3.5M
2021	0	0	0	1.2M
2020	266.7K	333.4K	400.1K	466.8K
2019	0	0	0	200.0K
2018	0	389.1K	389.1K	206.0K
2017	0	0	414.3K	183.1K
2016	0	375.4K	359.8K	344.2K
2012	422.2K	406.6K	0	0
2011	928.8K	683.3K	0	437.8K
2010	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Marker Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 24, 2022	kim anthony h.	acquired	-	-	150,512	chief financial officer
Mar 24, 2022	kim anthony h.	sold (taxes)	-17,489	0.4848	-36,076	chief financial officer
Mar 24, 2022	vera juan	acquired	-	-	140,823	chief scientific officer & coo
Mar 24, 2022	vera juan	sold (taxes)	-16,223	0.4848	-33,465	chief scientific officer & coo
Mar 24, 2022	hoang peter l.	acquired	-	-	199,094	president and ceo
Mar 24, 2022	hoang peter l.	sold (taxes)	-23,452	0.4848	-48,376	president and ceo
Jun 08, 2021	elms steve	acquired	-	-	12,658	-
Jun 08, 2021	wilson john robert	acquired	-	-	12,658	-
Jun 08, 2021	eansor norman david	acquired	-	-	12,658	-
Jun 08, 2021	laskow-pooley david	acquired	-	-	12,658	-

Which funds bought or sold MRKR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	MATRIX ASSET ADVISORS INC/NY	unchanged	-	-18,000	64,500	0.01%
Apr 03, 2024	Versant Capital Management, Inc	unchanged	-	-18.00	65.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.8	234,102	1,237,810	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	NEA Management Company, LLC	unchanged	-	1,028,570	5,892,850	0.39%
Feb 14, 2024	Creative Planning	unchanged	-	16,620	95,216	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-27.52	-1,782	12,837	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	160	979	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	17,773	108,614	-%
Feb 13, 2024	MORGAN STANLEY	added	85.46	10,982	19,790	-%

Are Funds Buying or Selling MRKR?

Are funds buying MRKR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRKR

No. of Funds

Unveiling Marker Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 03, 2023	aisling capital iv, lp	5.46%	464,285	SC 13D/A
Mar 26, 2021	new enterprise associates 16, l.p.	17.4%	14,464,285	SC 13D/A
Mar 24, 2021	leen ann m.	2.89%	2,415,842	SC 13D/A
Mar 15, 2021	eastern capital ltd	5.0%	3,966,668	SC 13D/A
Nov 13, 2020	eastern capital ltd	9.2%	4,466,668	SC 13D/A
Jun 18, 2020	eastern capital ltd	10.3%	4,883,335	SC 13D/A
Feb 20, 2020	eastern capital ltd	11.2%	5,300,002	SC 13D/A
Feb 14, 2020	perceptive advisors llc	0%	0	SC 13G/A

Recent SEC filings of Marker Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 08, 2024	8-K	Current Report
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	10-K	Annual Report
Mar 01, 2024	8-K	Current Report
Feb 26, 2024	8-K	Current Report

Peers (Alternatives to Marker Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Marker Therapeutics Inc News

Latest updates

Marker Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4	2018Q3	2018Q2	2017Q4	2017Q3	2016Q4	2016Q3
Revenue	310.1%	1,056,532	257,606	762,658	4,734,336	759,143	999,571	790,508	964,322	482,161	-	-	466,785	311,190	155,595	-	-	205,994	-	183,064	-	-
Operating Expenses	-45.8%	1,872,949	3,457,652	4,896,718	9,786,566	1,729,109	6,826,030	6,059,045	10,759,067	11,005,995	8,508,476	7,376,167	6,824,341	6,643,613	5,575,231	135,871,944	4,428,406	4,879,791	-	-	-	-
S&GA Expenses	-14.9%	1,202,754	1,412,672	2,518,725	2,515,824	1,424,670	3,234,133	3,135,168	3,733,001	2,988,570	2,525,000	2,572,562	2,547,289	2,826,995	1,914,097	17,177,835	2,551,146	3,052,954	-	-	-	-
R&D Expenses	-67.2%	670,196	2,044,980	2,377,993	7,270,742	304,439	3,591,897	2,923,877	7,026,066	8,017,425	5,983,476	4,803,605	4,277,052	3,816,618	3,661,134	2,649,223	1,877,260	1,826,837	-	-	-	-
EBITDA Margin	-Infinity%	-2.06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-Infinity%	-2.06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	6.0%	-2,803,066	-2,981,961	2,515,789	-4,967,576	-3,856,415	-6,919,583	-9,244,188	-9,910,508	-9,763,316	-8,507,227	-7,371,500	-6,341,699	-6,485,644	-5,079,162	-135,560,221	-4,388,406	-4,812,797	-	-	-	-
Net Income Margin	-56.4%	-1.21	-0.77	-1.04	-1.95	-3.32	-5.07	-8.06	-13.51	-33.73	-61.50	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-92.9%	-2,367,584	-1,227,280	-7,156,444	-5,988,116	-6,405,243	-7,745,784	-894,527	-12,325,883	-4,957,944	-5,604,017	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.1%	17.00	19.00	22.00	28.00	34.00	41.00	52.00	55.00	68.00	72.00	80.00	88.00	46.00	49.00	49.00	43.00	46.00	51.00	55.00	59.00	62.00
Current Assets	-12.1%	17.00	19.00	22.00	11.00	17.00	22.00	29.00	31.00	46.00	51.00	60.00	67.00	24.00	30.00	35.00	42.00	45.00	50.00	54.00	58.00	62.00
Cash Equivalents	-13.6%	15.00	17.00	18.00	6.00	12.00	18.00	26.00	29.00	43.00	49.00	57.00	65.00	21.00	27.00	32.00	40.00	44.00	48.00	53.00	58.00	62.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	10.6%	3.00	3.00	3.00	12.00	15.00	19.00	24.00	19.00	24.00	20.00	17.00	16.00	18.00	18.00	14.00	3.00	2.00	4.00	4.00	3.00	3.00
Current Liabilities	10.6%	3.00	3.00	3.00	5.00	8.00	11.00	13.00	8.00	13.00	8.00	6.00	4.00	6.00	6.00	5.00	3.00	2.00	3.00	3.00	3.00	3.00
Shareholder's Equity	-15.9%	14.00	17.00	19.00	16.00	20.00	23.00	28.00	36.00	44.00	52.00	63.00	72.00	27.00	31.00	35.00	39.00	44.00	48.00	51.00	56.00	59.00
Retained Earnings	-0.6%	-436	-433	-430	-433	-428	-424	-417	-408	-398	-388	-375	-365	-356	-347	-340	-334	-327	-322	-316	-311	-306
Additional Paid-In Capital	0.0%	450	450	450	449	448	447	445	444	442	441	439	437	384	378	375	373	372	370	368	367	365
Shares Outstanding	1.1%	9.00	9.00	9.00	9.00	8.00	8.00	8.00	8.00	8.00	8.00	7.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	23.00	-	-	-	23.00	-	-	-	164	-	-	-	65.00	-	-	-	199	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-110.0%	-2,367	-1,127	-7,056	-5,888	-6,305	-7,645	-794	-12,226	-4,858	-7,535	-6,785	-8,100	-5,504	-6,129	-4,302	-4,099	-4,560	-5,663	-4,179	-3,880	-6,162
Share Based Compensation	-18.1%	143	175	-120	660	383	935	356	1,631	1,467	1,468	1,652	1,377	1,253	1,270	1,361	1,345	1,283	1,184	1,363	1,526	14,403
Cashflow From Investing	-	-	-	18,777	-112	-127	-99.37	-2,266	-2,452	-349	-980	-399	-1,401	-4,100	-1,224	-3,828	-99.82	-12.86	-56.74	-82.26	-223	-147
Cashflow From Financing	-98.9%	5.00	479	736*	620	139	-	64.00	-	-	-	-100	52,657	4,000	2,186	-	550	-	753	-	63.00	63,763
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	72.00

MRKR Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 3,311,133	$ 3,513,544
Operating expenses:
Research and development	10,416,789	11,968,428
General and administrative	7,475,722	11,336,120
Total operating expenses	17,892,511	23,304,548
Loss from operations	(14,581,378)	(19,791,004)
Other income (expenses):
Arbitration settlement		(232,974)
Interest income	539,158	248,063
Loss from continuing operations before income taxes	(14,042,220)	(19,775,915)
Income tax expense	3,675
Net loss from continuing operations	(14,045,895)	(19,775,915)
Discontinued operations:
Loss from discontinued operations	(2,922,406)	(10,154,779)
Gain on disposal of discontinued operations, net of $63,000 in tax	8,731,487
Income (loss) from discontinued operations	5,809,081	(10,154,779)
Net loss	$ (8,236,814)	$ (29,930,694)
Net earnings (loss) per share:
Loss from continuing operations, basic	$ (1.59)	$ (2.37)
Income (loss) from discontinued operations, basic	0.66	(1.22)
Net loss per share, basic	(0.94)	(3.58)
Loss from continuing operations, diluted	(1.59)	(2.37)
Income (loss) from discontinued operations, diluted	0.66	(1.22)
Net loss per share, diluted	$ (0.94)	$ (3.58)
Weighted average number of common shares outstanding, basic	8,809,382	8,351,003
Weighted average number of common shares outstanding, diluted	8,809,382	8,351,003
Grant income
Revenues:
Total revenues	$ 3,311,133	$ 3,513,544

MRKR Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 15,111,450	$ 11,782,172
Prepaid expenses and deposits	988,126	1,849,239
Other receivables	1,027,815	2,402,004
Current assets of discontinued operations	0	585,840
Total current assets	17,127,391	16,619,255
Non-current assets of discontinued operations	0	17,802,929
Total assets	17,127,391	34,422,184
Current liabilities:
Accounts payable and accrued liabilities	1,745,193	2,521,193
Related party payable	$ 1,329,655
Other Liability, Current, Related Party, Type [Extensible Enumeration]	Related Party [Member]
Current liabilities of discontinued operations	$ 0	5,260,616
Total current liabilities	3,074,848	7,781,809
Non-current liabilities of discontinued operations	0	7,039,338
Total liabilities	3,074,848	14,821,147
Stockholders' equity:
Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at December 31, 2023 and 2022, respectively
Common stock, $0.001 par value, 30 million shares authorized, 8.9 million and 8.4 million shares issued and outstanding as of December 31, 2023 and 2022, respectively (see Note 10)	8,891	8,406
Additional paid-in capital	450,329,515	447,641,680
Accumulated deficit	(436,285,863)	(428,049,049)
Total stockholders' equity	14,052,543	19,601,037
Total liabilities and stockholders' equity	$ 17,127,391	$ 34,422,184

About Marker Therapeutics Inc

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.

CEO	Dr. Juan F. Vera M.D.
WEBSITE	markertherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	67

Marker Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Marker Therapeutics Inc? What does MRKR stand for in stocks?

MRKR is the stock ticker symbol of Marker Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Marker Therapeutics Inc (MRKR)?

As of Tue Apr 23 2024, market cap of Marker Therapeutics Inc is 39.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRKR stock?

You can check MRKR's fair value in chart for subscribers.

What is the fair value of MRKR stock?

You can check MRKR's fair value in chart for subscribers. The fair value of Marker Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Marker Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRKR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Marker Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MRKR is over valued or under valued. Whether Marker Therapeutics Inc is cheap or expensive depends on the assumptions which impact Marker Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRKR.

What is Marker Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, MRKR's PE ratio (Price to Earnings) is -4.79 and Price to Sales (PS) ratio is 5.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRKR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Marker Therapeutics Inc's stock?

In the past 10 years, Marker Therapeutics Inc has provided 0.36 (multiply by 100 for percentage) rate of return.